IL311400A - B7-h3 targeting fusion proteins and methods of use thereof - Google Patents

B7-h3 targeting fusion proteins and methods of use thereof

Info

Publication number
IL311400A
IL311400A IL311400A IL31140024A IL311400A IL 311400 A IL311400 A IL 311400A IL 311400 A IL311400 A IL 311400A IL 31140024 A IL31140024 A IL 31140024A IL 311400 A IL311400 A IL 311400A
Authority
IL
Israel
Prior art keywords
methods
fusion proteins
targeted fusion
targeted
proteins
Prior art date
Application number
IL311400A
Other languages
English (en)
Hebrew (he)
Original Assignee
Gt Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gt Biopharma Inc filed Critical Gt Biopharma Inc
Publication of IL311400A publication Critical patent/IL311400A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL311400A 2021-09-16 2022-09-15 B7-h3 targeting fusion proteins and methods of use thereof IL311400A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163245132P 2021-09-16 2021-09-16
PCT/US2022/043708 WO2023043955A1 (en) 2021-09-16 2022-09-15 B7-h3 targeting fusion proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
IL311400A true IL311400A (en) 2024-05-01

Family

ID=85603511

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311400A IL311400A (en) 2021-09-16 2022-09-15 B7-h3 targeting fusion proteins and methods of use thereof

Country Status (9)

Country Link
US (1) US20250145715A1 (enExample)
EP (1) EP4401776A4 (enExample)
JP (1) JP2024536791A (enExample)
KR (1) KR20240069748A (enExample)
CN (1) CN118119405A (enExample)
AU (1) AU2022347132A1 (enExample)
CA (1) CA3231445A1 (enExample)
IL (1) IL311400A (enExample)
WO (1) WO2023043955A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202547545A (zh) * 2024-01-26 2025-12-16 美商馬里亞納腫瘤學公司 靶向ｂ７－ｈ３之胜肽及其構築體
CN118894946A (zh) * 2024-07-24 2024-11-05 香港大学深圳医院 触发因子融合b7h3的原核表达方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10717965B2 (en) * 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
US11254744B2 (en) * 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
CN109562126A (zh) * 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
US12076343B2 (en) * 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy

Also Published As

Publication number Publication date
CA3231445A1 (en) 2023-03-23
KR20240069748A (ko) 2024-05-20
AU2022347132A1 (en) 2024-05-02
CN118119405A (zh) 2024-05-31
JP2024536791A (ja) 2024-10-08
EP4401776A4 (en) 2025-08-13
EP4401776A1 (en) 2024-07-24
US20250145715A1 (en) 2025-05-08
WO2023043955A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
DK4232463T3 (da) Interleukin-2-fc-fusionsproteiner og fremgangsmåder til anvendelses
IL287650A (en) Engineered chimeric fusion protein compositions and methods of use thereof
DK4186920T5 (da) Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse
DK3972987T3 (da) Antigenspecifik immunterapi til COVID-19-fusionsproteiner og fremgangsmåder til anvendelse deraf
AU2021365129A9 (en) Interleukin-2-fc fusion proteins and methods of use
IL288373A (en) flt3l-fc fusion proteins and methods of use
DK4073098T3 (da) Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse
EP3565579A4 (en) PD1-41BBL FUSION PROTEIN AND METHODS OF USE
DK3565828T3 (da) Sirp1 alpha-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
IL311400A (en) B7-h3 targeting fusion proteins and methods of use thereof
EP4447993A4 (en) GI TYPE FUSION PROTEINS AND THEIR USES
IL311301A (en) Anti-siglec-6 antibodies and methods of use thereof
EP3950720A4 (en) Fusion protein and use thereof
EP4171603A4 (en) ACE2-FC FUSION PROTEINS AND METHODS OF USE
IL304233A (en) Sialidase-antibody-her2 fusion proteins and methods of using them
IL285930A (en) Recombinant ccn domain proteins and fusion proteins
IL314048A (en) Anti-alk1 antibodies and methods of using the same
EP4429694A4 (en) RELAXIN-2 FUSION PROTEIN ANALOGUES AND METHODS OF USE THEREOF
EP4323412A4 (en) Fusion proteins and uses thereof
IL311296A (en) Pd-l1 targeting fusion proteins and methods of use thereof
IL304228A (en) Sialidase-antibody-pd-1 fusion proteins and methods of using them
EP3994180A4 (en) ANTIBODY-HER2-SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
IL312890A (en) Immunogenic fusion protein compositions and methods of use thereof
EP4355789A4 (en) TNFSF-L Fusion Proteins and Their Uses
EP4545571A4 (en) TRIPLE ACTIVITY FUSION PROTEIN AND ITS USE